RWE in Pharma: an expert panel discussion
In this panel discussion, a collection of experts, each with a range of experience, provide their insights into industry use of real-world evidence and data (RWE/D). We will discuss topics such as how RWE is important to understand disease and the ease of generation. Alongside this, we will investigate the challenges and developments facing RWE in light of COVID-19. All of this will be considered with a view towards the future, as the industry’s use of RWE continues evolving forward.
What will you learn?
- How the Pharma industry uses RWE, from practical evidence generation to how it can assist understanding and evaluation in healthcare
- How trust in RWE has developed, the changes responsible for this, alongside the present influences of data privacy and transparency
- The impact of COVID-19 on RWE, concerning the reputation of the data, any challenging consequences of COVID-19 and adaptations in working with RWE
Who may this interest?
- Data analysts
- Researchers
- RWE and HEOR managers
- Research and development
- Regulators
Speakers
Jennifer Christian
VP & GM, Medical & Scientific Services, US Real World Solutions
IQVIA (NC, USA)
Jennifer Christian is Vice President & General Manager of Medical & Scientific Services in US Real World Solutions at IQVIA (NC, USA), leading data scientists to support regulatory, payer and clinical decisions. Christian’s research strengthens the efficacy and safety of healthcare products.
She is an adjunct faculty member at Weill Cornell Medical College (NY, USA), a fellow of the National Academy of Medicine (MA, USA) and International Society of Pharmacoepidemiology (MA, USA) and a graduate of the UNC-Chapel Hill School of Pharmacy, UNC School of Public Health (both NC, USA) and Brown University School of Public Health (RI, USA).
Sreeram Ramagopalan
Global Head of Real-World Evidence (Market Access)
F. Hoffmann-La Roche (Basel, Switzerland)
Sreeram (Ram) Ramagopalan is the Global Head for Real World Evidence for Market Access at Roche (Basel, Switzerland). Ramagopalan’s team plans and executes real-world research to obtain and maintain access for innovative medicines. Ramagopalan holds a PhD in Epidemiology (University of Oxford, UK) and an MSc in Epidemiology (London School of Hygiene and Tropical Medicine, UK). Ramagopalan is interested in leveraging routine data for market access, alongside using novel data sources to understand the impacts of disease and benefits of treatment. An international expert, he has over 280 peer reviewed publications and is a regular speaker at international meetings.
Kourtney Davis
Vice President of Global Epidemiology
Janssen Pharmaceutical Companies of Johnson & Johnson (PA, USA)
Kourtney Davis is Vice President of Epidemiology for the Janssen Pharmaceutical Companies of Johnson & Johnson (Titusville, NJ). In this role, she is responsible for Janssen’s Epidemiology team in the pharmaceuticals sector, which focuses on real-world evidence supporting the safety of products across the Janssen portfolio, and ensuring that epidemiology strategies and deliverables are suitable to meet safety and benefit-risk-related evidence needs. With over 22 years of experience in the field, Kourtney is a Fellow of the International Society of Pharmacoepidemiology (MD, USA). She holds a PhD and MSPH qualifications in Epidemiology from the University of North Carolina at Chapel Hill (NC, USA), where she served as adjunct Assistant Professor for more than a decade.
Catia Proenca
Director in GMA-RWE
Alira Health (MA, USA)
Catia Proenca has a diverse background with over 10 years of experience across the pharmaceutical industry, consulting, and academia in RWE, pre-clinical research and market access. Catia’s experience spans several therapeutic areas including neuroscience, cardiometabolic, hematology, oncology and respiratory. At Alira Health (Basel, Switzerland), Catia works across the RWE, and Market Access teams, with close links with Patient Engagement, to design evidence generation strategies that support health technology assessment and patient needs. Additionally, Catia provides strategic insights and recommendations on clinical trial design to optimize medicine access to patients, supports the development of evidence gap analyses, objection handling and market access strategies.
Catia completed a post-graduation in epidemiology at the London School of Hygiene and Tropical Medicine (UK). She holds a PhD in Neuroscience from the Weill Cornell Medical College (NY, USA) and the University of Lisbon (Portugal).
In association with
